| 王璋琰,洪煌明,林桐榆.淋巴瘤患者CAR-T治疗后毒副反应的管理与桥接治疗的研究进展[J].中国肿瘤,2025,34(9):734-741. |
| 淋巴瘤患者CAR-T治疗后毒副反应的管理与桥接治疗的研究进展 |
| Management of Toxicities After Chimeric Antigen Receptor T-cell Therapy and Progress of Bridging Therapy in Lymphoma Patients |
| 投稿时间：2025-05-27 |
| DOI：10.11735/j.issn.1004-0242.2025.09.A007 |
|
 |
| 中文关键词: 嵌合抗原受体T细胞疗法 淋巴瘤 毒副反应 细胞因子释放综合征 桥接治疗 |
| 英文关键词:chimeric antigen receptor T-cell therapy lymphoma toxicities cytokine release syndrome bridging therapy |
| 基金项目:国家自然科学基金项目（U24A20679；82470237）；中山大学肿瘤防治中心高层次人才特殊支持计划 （CIRP-SYSUCC-0022） |
|
| 摘要点击次数: 254 |
| 全文下载次数: 121 |
| 中文摘要: |
| 摘 要：嵌合抗原受体T细胞（chimeric antigen receptor T-cell，CAR-T）疗法作为一种革命性的免疫疗法，近年来在血液系统恶性肿瘤的治疗中取得了显著成效，但其临床应用受到毒副反应的制约。桥接治疗作为单个核细胞采集至 CAR-T 细胞回输期间的补充治疗，通过化疗、放疗、靶向治疗及免疫治疗等方式降低肿瘤负荷、调节免疫微环境，在延缓疾病进展的同时对毒副反应产生重要影响。全文系统综述了CAR-T疗法的主要毒副反应及管理策略，深入分析了不同桥接治疗方式影响毒副反应的潜在机制，旨在为CAR-T疗法的临床应用提供科学依据和实践指导。 |
| 英文摘要: |
| Abstract： Chimeric antigen receptor T-cell (CAR-T) therapy, as a revolutionary immunotherapy, has achieved significant clinical efficacy in the treatment of hematologic malignancies in recent years. However, its clinical application remains limited by associated toxicities. Bridging therapy, as a supplementary antitumor treatment administered between leukapheresis and CAR-T cell infusion, reduces tumor burden and modulates the immune microenvironment through chemotherapy, radiotherapy, targeted therapy, and immunotherapy. It not only delays disease progression but also significantly influences the toxicities associated with subsequent CAR-T therapy. This paper reviews the main types of toxicities and management strategies of CAR-T therapy, and analyzes the role of bridging therapy in managing these toxicities, conducting an in-depth analysis of the potential mechanisms by which different bridging therapy modalities influence these toxicities, to provide scientific basis and practical guidance for the clinical application of CAR-T therapy. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|